XP-21279

XP-21279
Clinical data
Other namesXP21279
Routes of
administration		Oral[1][2][3]
Drug classDopamine precursor; Dopamine receptor agonist
Identifiers
  • [(2R)-1-[(2S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoyl]oxypropan-2-yl] benzoate
CAS Number
PubChem CID
DrugBank
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H21NO6
Molar mass359.378 g·mol−1
3D model (JSmol)
  • C[C@H](COC(=O)[C@H](CC1=CC(=C(C=C1)O)O)N)OC(=O)C2=CC=CC=C2
  • InChI=1S/C19H21NO6/c1-12(26-18(23)14-5-3-2-4-6-14)11-25-19(24)15(20)9-13-7-8-16(21)17(22)10-13/h2-8,10,12,15,21-22H,9,11,20H2,1H3/t12-,15+/m1/s1
  • Key:AKUWZLYXAADOTQ-DOMZBBRYSA-N

XP-21279 is a sustained-release levodopa (L-DOPA) prodrug and hence a dopamine precursor and non-selective dopamine receptor agonist which was under development for the treatment of Parkinson's disease.[4][1][3] It is taken by mouth.[1][2][3]

  1. ^ a b c Hauser RA (2011). "Future treatments for Parkinson's disease: surfing the PD pipeline". The International Journal of Neuroscience. 121 Suppl 2: 53–62. doi:10.3109/00207454.2011.620195. PMID 22035030.
  2. ^ a b Cite error: The named reference Ondo2014 was invoked but never defined (see the help page).
  3. ^ a b c Freitas ME, Ruiz-Lopez M, Fox SH (November 2016). "Novel Levodopa Formulations for Parkinson's Disease". CNS Drugs. 30 (11): 1079–1095. doi:10.1007/s40263-016-0386-8. PMID 27743318.
  4. ^ "XP 21279". AdisInsight. Springer Nature Switzerland AG. 26 May 2022. Retrieved 27 September 2024.